Adapalene/clindamycin - Lee's Pharmaceutical

Drug Profile

Adapalene/clindamycin - Lee's Pharmaceutical

Alternative Names: Clindamycin/adapalene; ZK-008

Latest Information Update: 06 Jul 2017

Price : $50

At a glance

  • Originator Lees Pharmaceutical Holdings
  • Class Antiacnes; Antibacterials; Keratolytics; Lincosamides; Retinoids; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acne vulgaris

Most Recent Events

  • 29 Jun 2017 Efficacy and pharmacokinetics data from a phase I/II trial in Acne vulgaris released by Lees Pharmaceutical Holdings
  • 29 Jun 2017 Lee’s Pharmaceutical plans a phase III trial for Acne Vulgaris in China
  • 24 Mar 2015 Phase-I/II clinical trials in Acne vulgaris in China (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top